EcoDrugPlus

Polo Like Kinase 1

Ensembl ID : ENSDNOG00000017616
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSDNOG00000018711
Gene Symbol: PLK4
2 Cross references
215 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 1

Ensembl ID : ENSDNOG00000012059
Gene Symbol: PARP1
4 Cross references
207 Possible Orthologues:

Poly(Adp-Ribose) Polymerase 2

Ensembl ID : ENSDNOG00000017471
Gene Symbol: PARP2
4 Cross references
186 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSDNOG00000000110
Gene Symbol: PORCN
4 Cross references
266 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily M Alpha 1

Ensembl ID : ENSDNOG00000006262
Gene Symbol: KCNMA1
2 Cross references
297 Possible Orthologues:

Potassium Calcium-Activated Channel Subfamily N Member 4

Ensembl ID : ENSDNOG00000044059
Gene Symbol: KCNN4
4 Cross references
191 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSDNOG00000043490
Gene Symbol: KCNJ11
4 Cross references
190 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSDNOG00000016797
Gene Symbol: KCNJ2
4 Cross references
273 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSDNOG00000042600
Gene Symbol: KCNJ3
4 Cross references
229 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSDNOG00000044283
Gene Symbol: KCNJ5
4 Cross references
213 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSDNOG00000008257
Gene Symbol: KCNK2
2 Cross references
284 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).